David A. Santos - Dec 28, 2022 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP, Chief Commercial Officer
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
Dec 28, 2022
Transactions value $
$0
Form type
4
Date filed
12/30/2022, 03:30 PM
Previous filing
Jan 26, 2022
Next filing
Jan 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Award $0 +50K $0.00 50K Dec 28, 2022 Common Stock 50K $2.42 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted an option with a performance-based condition with respect to 50,000 shares of common stock on January 24, 2022. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On December 28, 2022, it was determined that the performance metric had been met.
F2 The option was fully vested on December 28, 2022, the date the determination was made that the performance metric had been met.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney